


ASX ANNOUNCEMENT



Eastland Medical Systems Ltd

www.eastlandmedical.com.au

14th April 2008

WORLD'S FIRST PRESENTATION ON SUBLINGUAL ANTI- MALARIA TREATMENT - ArTiMist™

Eastland Medical Systems Limited (Eastland®) advises that today the Company is hosting the World's First Presentation by the eminent U.K. scientist, Mr. Calvin Ross who is presenting the development of the new and revolutionary sublingual anti-malaria treatment primarily for children - ArTiMist™, at the Sofitel Wentworth Hotel Sydney.

Attached is a copy of Mr. Ross's presentation and biography. This information can also be accessed via the Company's website www.eastlandmedical.com.au

Trevor Strahan.
Company Secretary
Eastland Medical Systems Ltd

ArTiMist™ Clinical Trial Results

By

Mr Calvin Ross

Sofitel Wentworth Hotel

Sydney

14 April 2008

Eastland Medical Systems Ltd

Norwich Facility



Norwich Facility



Norwich Facility



Norwich Facility



Malaria Focus-Mission

- Produce a Product suitable for the treatment of Malaria in Infants and Young Children
- To conduct Studies in South Africa and Malaysia
- To conduct Clinical trials in Africa and Asia
- To Produce a Stable Commercial Product

Malaria Facts

- 500 million cases reported annually
- 200 million of these are children
- **Most deaths in Children are aged “Under 5.”**
- ***Most Deaths in Africa!***
- Over 40% of the planet population exposed
- Malaria on the increase due to global changes in weather and temperature

Malaria Reality in Infants

- Fever
- Dehydration
- Vomiting
- Diarrhoea
- Poor nutrition
- Comatose
- Death

Current Treatments

1. Oral Tablets and Syrups
2. Injections
3. Suppository
4. ACT's or Combined Treatments
5. Others

Sublingual Spray Product

- Multi dose pack
- 50 dose pack
- Approved Materials
- Api (DMF in place)
- Analytical methods in place
- Stable formulation

Sublingual Advantage - ArTiMist™

Main Points

- Easy to administer
- No drug to swallow
- Rapid absorption
- Avoids first pass effect
- Single multi dose pack
- Can be used in remote areas
- Simple training required
- Easy to store
- Improved bio availability ?

Manufacture of Product

- Phase I material will be manufactured in Licensed premises in the UK
- Clinical phase manufacture UK
- Commercial phase UK & Germany
- Full production Germany

Phase I studies

- Clinical studies: Conducted in South Africa and Malaysia
- Single dose study in Malaysia and a multi dose study in South Africa
- Clinics located in both regions
- Completed March 2008

Phase I Study Results

- A Phase I open labelled Randomized trial to determine the Pharmacokinetics, bioequivalence and relative bio availability of Artemether when administrated as a 3mg/actuation sublingual spray, 6mg/actuation sublingual spray and oral tablets in 16 healthy male subjects.
- Results showed the sublingual route has higher bio availability when compared to the oral route.
- Artemether sublingual spray 3mg strength and 6mg strength are equivalent when given at the same total dose.
- Cmax of Artemether and Dihydroartemisinin has proven dose proportionality.
- Overall, Artemether delivered as a sublingual spray is as safe and as well tolerated as the oral route.

Clinical Programme Requirement

- Regulatory – Technical Brief
- Trial requirements in a single/multi dose study
- Phase I - 32 subjects
- Phase III – 300 patients
- Toxicity data exists (in public domain)
 1. Literature only required
 2. No further animal studies
 3. Local toleration study required
- Pump spray delivery system
- Back up requirements in place
- Drug Master File in place

The Conclusion for ArTiMist™

- Superior to Tablet Formulation
- Stable Formulation
- Dose Proportional
- No side effects during trials
- *Fit For Purpose !*



Biography - Calvin Ross

Calvin Ross is a Pharmacologist who has spent most of his life dedicated to working in the field of drug delivery, design and formulation improvement in therapeutic areas. He leads the world in the development of sublingual aerosol and spray formulation, and device development. He is also one of the leading experts in the field of pharmaceutical aerosols.

Mr Ross is the founder and Research and Development Director of Norwich Pharma Ltd and ProtoPharma Ltd. He is an inventor and developer of novel pharmaceutical products for international markets and is responsible for the development and clinical trials for the sublingual anti-malaria treatment primarily for children – [ArTiMist](#).

Mr Ross has focused on the therapeutic areas of Malaria, Pain Management and Drug Addiction throughout his career. He has held senior development roles with Bespack, Sosei Group, Dallas Burston Group, Terumo and Bioglan Plc.